GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -13,162 | -9,387 | -5,976 | -2,266 | -7,597 |
| Accounts payable and accrued liabilities | 937 | N/A | -1,231 | -1,347 | N/A |
| Other Working Capital | 828 | -402 | -1,169 | -1,343 | 1,937 |
| Other Operating Activity | -1,507 | -647 | 677 | 793 | -3,192 |
| Operating Cash Flow | $-12,904 | $-10,436 | $-7,699 | $-4,163 | $-8,852 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 12,893 | 12,892 | 12,893 | N/A | -2,009 |
| Sale Of Investment | N/A | N/A | N/A | 5,034 | N/A |
| Investing Cash Flow | $12,893 | $12,892 | $12,893 | $5,034 | $-2,009 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 2,976 | 2,976 | 2,976 | N/A | 6,268 |
| Financing Cash Flow | $2,976 | $2,976 | $2,976 | $N/A | $6,268 |
| Beginning Cash Position | 1,079 | 1,079 | 1,079 | 1,079 | 5,672 |
| End Cash Position | 4,044 | 6,511 | 9,249 | 1,950 | 1,079 |
| Net Cash Flow | $2,965 | $5,432 | $8,170 | $871 | $-4,593 |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,904 | -10,436 | -7,699 | -4,163 | -8,852 |
| Free Cash Flow | -12,904 | -10,436 | -7,699 | -4,163 | -8,852 |